Therapeutic Area

GIP Receptor Agonist and Amylin Analog

Therapeutic area intelligence for GIP Receptor Agonist and Amylin Analog with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Roche →

Assets

Enicepatide →

Recent signals(2)

CompetitiveJune 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

CompetitiveJune 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Obesity →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.